VERAXA (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, announced that its VXA-222 bispecific antibody-drug conjugate (bsADC) program has advanced beyond the discovery phase and into the next stage of development. This milestone marks successful completion of the discovery portion of VERAXA's collaboration with OmniAb Inc., which began in May 2025 (https://nnw.fm/nIprz). With discovery work completed, VERAXA will now focus on building the final therapeutic candidate by combining the antibody binders identified through the collaboration with its own proprietary linker and conjugation technologies.
While VXA-222 is not based on VERAXA's BiTAC platform, it leverages the company's antibody engineering expertise and represents one of its more advanced development programs. The advancement of VXA-222 is a critical step for VERAXA as it continues to build a diversified oncology pipeline spanning bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats targeting difficult-to-treat cancers.
In parallel with the program's progress, VERAXA has expanded its intellectual property portfolio with its first BiTAC-related patent filings, alongside additional patents supporting conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, with newly filed applications expected to extend protection into at least 2047.
The expansion of VERAXA's patent estate is crucial for protecting its innovative technologies and maintaining a competitive edge in the rapidly evolving field of antibody-based cancer therapies. The company's strategic focus on broadening its IP portfolio underscores its commitment to long-term growth and its position as a leader in next-generation antibody technologies.
VERAXA's continued progress in advancing its pipeline and expanding its intellectual property highlights the company's dedication to developing novel therapies that could address significant unmet medical needs in oncology. With several programs in development, including the VXA-222 bsADC, VERAXA is well-positioned to make meaningful contributions to cancer treatment.
For more information on VERAXA and its pipeline, visit the company's newsroom at https://ibn.fm/VRXA.
